Depression affects approximately 2. 5% of children and 8% of adolescents. Escitalopram is the
S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake
inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to
provide a systematic evaluation of the safety and efficacy of escitalopram in the treatment
of depressed pediatric patients, 12 to 17 years of age. Patients completing the study will be
eligible to enter an open-label extension study.
Inclusion Criteria:
- Patient must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV)
diagnostic criteria for Major Depressive Disorder.
- Patient's current depressive episode must be at least 12 weeks in duration
- Patient must have a parent or caregiver who must agree to accompany the patient to all
clinic visits.
Exclusion Criteria:
- Patients who currently meet DSM-IV criteria for:
1. attention deficit-hyperactivity disorder
2. obsessive-compulsive disorder
3. posttraumatic stress disorder
4. bipolar disorder
5. pervasive developmental disorder
6. mental retardation
7. conduct disorder
8. oppositional defiant disorder
- Patients who are considered a suicide risk (have active suicidal ideation), who have
made a suicide attempt, or who have ever been hospitalized because of a suicide
attempt.
PCSD - Feighner Research, San Diego, California 92111, United States
University of California at Davis, MIND Institute, Health Services, Sacramento, California 95817, United States
UCSD Outpatient Psychiatry Services, San Diego, California 92103, United States
Children's National Medical Center, Washington, District of Columbia 20010, United States
University of Florida - Child Study Program, Gainesville, Florida 32610, United States
Janus Center for Psychiatric Research, West Palm Beach, Florida 33407, United States
Clinical Neuroscience Solutions, Inc., Jacksonville, Florida 32216, United States
Kolin Research Group, Winter Park, Florida 32789, United States
Capstone Clinical Research, Libertyville, Illinois 60048, United States
Clinco, Terre Haute, Indiana 47802, United States
Psychiatric Associates, Overland, Kansas 66211, United States
Capitol Clinical Research Associates, Rockville, Maryland 20852, United States
Pharmasite Research, Inc., Baltimore, Maryland 21208, United States
St. Charles Psychiatric Associates, St. Charles, Missouri 63301, United States
Creighton University Medical School, Department of Psychiatry, Omaha, Nebraska 68131, United States
CNS Research Institute, Clementon, New Jersey 08021, United States
Pulmonary and Allergy Associates, P. A., Summit, New Jersey 07901, United States
North Carolina Neuropsychiatry, PA, Chapel Hill, North Carolina 27514, United States
University Hospitals of Cleveland, Division of Child & Adolescent Psychiatry, Cleveland, Ohio 44106, United States
University of Cincinnati College of Medicine, Children's Hospital Medical Center, Cincinnati, Ohio 45229, United States
IPS Research Company, Oklahoma City, Oklahoma 73103, United States
Drexel University College of Medicine, Friends Hospital, Philadelphia, Pennsylvania 19124, United States
University of Pennsylvania, Department of Psychiatry, Mood & Anxiety Disorders Section, Philadelphia, Pennsylvania 19104, United States
Clinical Neuroscience Solutions, Memphis, Tennessee 38119, United States
University of Texas Medical Branch, Department of Psychiatry & Behavioral Sciences, Galveston, Texas 77555, United States
University of Texas Southwestern Medical Center, Center for Pediatric Psychiatry, Dallas, Texas 75235, United States
Brighton Research Group, LLC, Virginia Beach, Virginia 23452, United States
Northwest Clinical Research Center, Bellevue, Washington 98004, United States
